Danaher Appoints Greg Milosevich as Executive Vice President
Danaher Corporation (NYSE: DHR), a notable entity in life sciences and diagnostics innovation, recently announced a significant leadership change. Greg Milosevich has been appointed by the Board of Directors as the Executive Vice President responsible for the Life Sciences division. This promotion is set to take effect on July 1.
Milosevich's Ascension Within Danaher
Before this promotion, Milosevich had been serving as Vice President and Group Executive of the Life Sciences Innovations Group since 2021. His ascent to this prominent role marks a step forward in Danaher’s leadership strategy.
Rainer Blair, the President and Chief Executive Officer of Danaher, expressed his confidence in Milosevich's leadership abilities. He noted Milosevich's essential contributions to advancing the Life Sciences Innovations Group over the past years. Blair lauded his dedication to delivering strong results, customer engagement, and team building, qualities that align well with the Danaher Business System ethos.
Milosevich's Career Journey
Milosevich’s journey with Danaher began in 2010 when the company acquired Molecular Devices. Over the years, he has held several key positions that reflect a trajectory of increased responsibility and leadership. Most notably, his role as Vice President involved overseeing multiple facets of the company’s operations, including prominent names such as Beckman Coulter Life Sciences, Sciex, and Leica Microsystems.
Diversity in Innovations and Leadership
His educational background complements his professional experience, as he earned a bachelor's degree in physics from the University of Puget Sound, graduating with the highest honors. This combination of educational excellence and extensive industry experience places Milosevich in a unique position to lead Danaher’s innovative pursuits in life sciences.
About Danaher Corporation
Danaher Corporation stands out as a leader in the global life sciences and diagnostics fields, with a commitment to harnessing science and technology to enhance global health outcomes. The company collaborates closely with various stakeholders to tackle critical health challenges faced by patients internationally. By leveraging advanced scientific methods and technologies, Danaher helps facilitate quicker and more precise diagnostics and reduces both the time and expense needed to discover and deliver effective therapies. With a workforce comprising approximately 63,000 associates worldwide, Danaher emphasizes scientific excellence, innovation, and ongoing improvement in its operations and offerings.
Frequently Asked Questions
Who is Greg Milosevich?
Greg Milosevich is the newly appointed Executive Vice President for Life Sciences at Danaher Corporation, effective July 1.
What role did Milosevich hold before his promotion?
Before his new position, Milosevich served as Vice President and Group Executive of the Life Sciences Innovations Group.
How long has Milosevich been with Danaher?
He has been with Danaher since 2010, following the acquisition of Molecular Devices.
What is Danaher Corporation known for?
Danaher Corporation is recognized for its contributions to life sciences and diagnostics, focusing on innovative technologies that improve healthcare.
How many employees does Danaher have worldwide?
Danaher employs about 63,000 associates globally, dedicated to scientific excellence and health innovation.
